Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore (Nasdaq: IMCR) announced management participation in several investor conferences in September 2026. The Company will host fireside chats at the Cantor Global Healthcare Conference on September 10 at 2:45 p.m. EDT, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 2:35 p.m. EDT, and the Baird 2026 Global Healthcare Conference on September 15 at 12:15 p.m. EDT. Immunocore will also hold 1x1 and small group meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 16. Presentations will be webcast live with replays available for a limited time via the Investors section of Immunocore’s website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

Cantor Global Healthcare Conference 2026
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. EDT

Morgan Stanley 24^th Annual Global Healthcare Conference
Fireside Chat: Monday, September 14, 2026, at 2:35 p.m. EDT

Baird 2026 Global Healthcare Conference
Fireside Chat: Tuesday, September 15, 2026, at 12:15 p.m. EDT

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 and small group meetings: Wednesday, September 16, 2026

The presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Vice President Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Ryan Baker, Vice President of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When will Immunocore (IMCR) present at the Cantor Global Healthcare Conference 2026?

Immunocore will present at the Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026, at 2:45 p.m. EDT. According to Immunocore, this will be a fireside chat featuring company management as part of its September investor conference schedule.

What is the schedule for Immunocore (IMCR) at the Morgan Stanley 24th Annual Global Healthcare Conference 2026?

Immunocore is scheduled for a fireside chat on Monday, September 14, 2026, at 2:35 p.m. EDT at the Morgan Stanley 24th Annual Global Healthcare Conference. According to Immunocore, this appearance is part of a series of September investor engagements.

How can investors access the Immunocore (IMCR) September 2026 conference webcasts?

Investors can access the live webcasts by visiting the “Events & Presentations” section under “Events” in the Investors area of Immunocore’s website. According to Immunocore, replay recordings will be available online for a limited period after the events.

What is Immunocore’s (IMCR) participation at the H.C. Wainwright 28th Annual Global Investment Conference 2026?

Immunocore will participate in 1x1 and small group meetings on Wednesday, September 16, 2026, at the H.C. Wainwright 28th Annual Global Investment Conference. According to Immunocore, these meetings provide opportunities for direct interaction with institutional investors and analysts.

What does Immunocore (IMCR) develop and what is KIMMTRAK approved for?

Immunocore develops ImmTAX TCR bispecific immunotherapies targeting cancer, autoimmune and infectious diseases. According to Immunocore, its lead oncology therapy KIMMTRAK is approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, EU, Canada, Australia and the UK.